Peritoneal Surface Oncology Group International

PSOGI is a collaboration of world–renowned experts on the treatment of peritoneal cancer, founded & chaired by Paul Sugarbaker PSOGI aims to improve outcomes of patients with PC by educating patients, training physicians, organizing meetings & performing basic & clinical research

Intersting work published about the variability interobserver when the peritoneal lessions are classified and define. Nice multicenter study published in @AnnSurgOncol by @writeslkpushkin and @glehenolivier @indepso @PSOGI_EC @cirugiacancer @aecirujanos link.springer.com/article/10.124…

Official Photo of 2026 Singapore SingHealth Peritoneal Surface Oncology 9 to 10 March 2026 Conference WORKSHOP Comprehensive Management of Peritoneal Surface Malignancy Workshop & PIPAC Course 11 to 13 March 2026 SPSOC @PSOGI_EC @IspsmHipec @ISSPP1

Nice meeting in Phoenix Arizona @SocSurgOnc 2026 @aecirujanos @HUReinaSofia @cirugiacancer @PSOGI_EC youtu.be/2dtX2ce8xJk

Announcing the 3rd Biennial Conference of the Oncology Group of Pune on Peritoneal Surface Malignancy & Gynecologic Oncology. 🗓 17–19 Sept 2026 📍 Pune A focused meeting addressing the complexities and dilemmas in peritoneal surface oncology. Highlights: 🔬 Pre-conference Cadaveric Workshop on Cytoreductive Surgery & Peritonectomy 🧠 Didactic lectures & panel discussions 🔎 Live pathology workshop 🌍 Stellar international & national faculty Featuring renowned international experts including Prof. @PSugarbaker , Prof. @glehenolivier , Prof. Artem Stepanyan & Prof. Lana Bijelic. Join us in Pune to exchange ideas, debate dilemmas, and advance care in peritoneal surface malignancy. @writeslkpushkin @PSOGI_EC @IASO_IJSOonline @sukumar_vivek @MufaddalKazi @avanishsaklani @zeebausofi #CRS #HIPEC #SurgicalOncology #GynecOnc #PeritonealSurfaceMalignancy

📅 C'est le moment de vous inscrire pour notre prochain #RDVAAMARAPE lundi 23 mars à 20h sur le sujet du #mesotheliome #péritonéal avec le Dr @VahanKepenekian des @CHUdeLyon Rdv nombreux ! Inscriptions avant le 20 mars. #maladierares #cancersrares

Laparoscopic management of peritoneal disease international consensus has been published in @BJSAcademy recommendations about staging and CRS +HIPEC laparoscopy from a panel of experts @PSOGI_EC @somusp9 @PSOGI_EC @ISSPP1 @ChiaClaramae @aecirujanos academic.oup.com/bjs/advance-ar…

Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei | Journal for ImmunoTherapy of Cancer share.google/SZZIstJCtTgnL0…

Occult peritoneal spaces- surgical anatomy, exploration and resection of... youtu.be/SoYPvXyTRkU?si… via @YouTube New video released on the PSOGI YouTube channel @PSOGI_EC" target="_blank" rel="nofollow noopener">youtube.com/@PSOGI_EC

A novel BRCAm classification system reveals differential responses to PARP inhibition and prognostic outcomes in eOC: a multicenter study in @ESMO_Open. New BRCA1m classification system identifies superior PARPi response in DBD/DBD-BRCT region. esmoopen.com/article/S2059-…

We hope everyone on their way to Copenhagen 🇩🇰 for ESGO 2026 has a good journey this week! 🚊 ✈️🚙 🚇 As part of our commitment to sustainability ♻️, each of the 3,500+ delegates will receive a free or discounted public transportation pass to use during the congress. (Please check your email for the instructions to access it!). The venue, Bella Center, is conveniently located directly at a metro stop, making it easy to access by public transport from the airport or train station and saving you a taxi ride. 🤓 Need some reading material on your way to the Congress? All accepted abstracts to ESGO 2026 have been published as a supplement in the International Journal of Gynecological Cancer. 🙌 You can also already get a head start browsing all the ePosters online or on the ESGO Events app—make sure to take note of which paper poster you’ll nominate as the winner of this year’s Best Poster! See you soon! #gynonc

Can #indocyanine green enhance detection of #residual #ovarian cancer after #NACT? ICG + NIR imaging after NACT ⬆️ detection of #microscopic malignant foci by 25% compared to white light alone! More #occult peritoneal disease identified ✅ 🔗 bit.ly/40mR4t2 @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @RParejaGineOnco @lchiv4 @annafagottimd @HousseinELHAJJ3 @AinhoaMada @luribero26 @beatesarta @AlwynDO @PeppeParisi_ @ilkerselcukmd @VinTarantino @NSeminario27498 @dranushak88 #IJGConline #Research #Prevention #Treatment #Diagnostic #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc

Oncologic outcomes of incidental #STIC & associated #HGSC in high-risk patients undergoing #risk-reducing surgery. 📌 Isolated STIC → 9% progression to primary peritoneal carcinoma 📌 Concomitant microscopic HGSC/STIC → 30% recurrence despite treatment 📊 10-yr OS: 87.5% (isolated) vs 67% (concurrent) 🔎 Pathologic excellence (SEE-FIM) + vigilant surveillance are critical. Timely RRS remains key. 🔗 bit.ly/3MoNTho @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @RParejaGineOnco @lchiv4 @annafagottimd @HousseinELHAJJ3 @AinhoaMada @luribero26 @beatesarta @AlwynDO @PeppeParisi_ @ilkerselcukmd @VinTarantino @NSeminario27498 @dranushak88 #IJGConline #Research #Prevention #Treatment #Diagnostic #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc

MIDCON 2026, the mid-term national conference of the Indian Association of Surgical Oncology in Raipur. I spoke on management of Colorectal Peritoneal Metastasis in the Era of systemic therapy.; — discussing our recent meta-analysis and the implications of the CAIRO6 trial.

Omic analysis of the protein profile in digestive tumours, from proteo... Read our last manuscript reviewing the use of proteomics in digestive tumors. @aecirujanos @myESMO @ISSPP1 @PSOGI_EC @HUReinaSofia @IMIBIC @indepso sciencedirect.com/science/articl…

Exploring uterine #leiomyosarcoma variants 🧬✨ Clinico-pathological characteristics and survival outcome associated with uterine leiomyosarcoma variants 💡 bit.ly/4r93wZm @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @luribero26 @beatesarta @AlwynDO @PeppeParisi_ @ilkerselcukmd @VinTarantino @NSeminario27498 @dranushak88

🩵🎉 First accredition as an ESGO centre of excellence in S.Korea

Complex multimodal management of recurrent ovarian serous papillary carcinoma highlights the importance of persistent MDT-driven decision-making and surgical reassessment: ▶️ The patient was diagnosed with ovarian serous papillary carcinoma in 2021. Initial management consisted of six cycles of neoadjuvant chemotherapy (NAC) with carboplatin and paclitaxel, followed by interval debulking surgery. Postoperatively, she received six additional cycles of systemic chemotherapy with the same platinum-taxane regimen. ▶️ During follow-up, approximately six months later, tumor markers demonstrated biochemical progression. She subsequently underwent four cycles of second-line chemotherapy with gemcitabine, carboplatin, and bevacizumab, achieving a radiological and biochemical response. ▶️ In 2023, she underwent cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin. ▶️ In 2024, imaging revealed an isolated left axillary lymph node metastasis. This was treated with six cycles of liposomal doxorubicin and carboplatin, resulting in a favorable response. ▶️ In 2025, the patient underwent second-look surgery, which demonstrated no evidence of disease (NED) within the peritoneal cavity. During the same operation, a ventral incisional hernia repair was performed using component separation and sublay mesh reinforcement. Concurrent left axillary lymph node sampling showed metastasis in 1 of 4 nodes. Postoperatively, she received four additional cycles of liposomal doxorubicin and carboplatin, after which she again achieved NED status. She was then followed without chemotherapy for six months. Subsequent surveillance imaging identified metabolically active abdominal lymph nodes. The patient received four further cycles of liposomal doxorubicin and carboplatin, with radiological response. ⏭️ Given the persistence of metabolically active abdominal lymph nodes despite systemic therapy, the multidisciplinary tumor board recommended surgical lymphadenectomy. At surgery, despite the patient’s history of multiple prior abdominal procedures and complex abdominal wall reconstruction, extensive adhesiolysis allowed thorough exploration. No peritoneal metastases were identified, and the procedure confirmed absence of macroscopic peritoneal disease (NED in the peritoneum). We performed a targeted lymphadenectomy for metabolically persistent infrarenal and retrocaval nodes after extensive multimodal treatment for recurrent ovarian serous papillary carcinoma. ⚠️ This case underscores the evolving role of selective surgical intervention in oligometastatic ovarian cancer within a multimodal treatment strategy. 🙏 We welcome your questions, insights, and comments. #OvarianCancer #CRS #HIPEC #GynecologicOncology #surgicaloncology #peritonealsurfacemalignancies #psogi

#RDV @AssocAmarape 🙏Un grand merci à la Dr Valéria de Franco sur le #PseudomyxomePeritoneal #PMP #Cancer #Maladiesrares #Cancerrares et merci à toutes et à tous pour votre participation 💪👍

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in peritoneal sarcomatosis: Therapeutic advancement or clinical controversy? An institutional review ⁦@SurgJournal⁩ surgjournal.com/article/S0039-…

youtu.be/TWFb8Y3IW0o?is… @PSOGI_EC